The US Food and Drug Administration “is struggling” to adapt procedures that sped up the development of COVID-19 vaccines to other disease areas due to inadequate resources and staffing challenges, Centers for Biologics Evaluation and Research Director Peter Marks said.
Marks credited FDA’s pivot to providing drug manufacturers with real-time feedback as the top reason the US was able to...